Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Atara Biotherapeutics, Inc. (ATRA) AI Forecast

Our AI analyzed Atara Biotherapeutics, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$ATRA Neutral Signal Full forecast available
Sign Up Free

Atara Biotherapeutics, Inc. (ATRA) Stock Forecast Sept. 5, 2026

Atara Biotherapeutics, Inc. (ATRA) AI Stock Price Forecast & Investment Analysis

Atara Biotherapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Atara Biotherapeutics, Inc. (ATRA) - Comprehensive Stock Analysis & Investment Research

Deep dive into Atara Biotherapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 5, 2026, 1:46 p.m. (UTC)

Atara Biotherapeutics, Inc. Investment Summary

When evaluating whether Atara Biotherapeutics, Inc. (ATRA) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Atara Biotherapeutics, Inc. (ATRA) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $92 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Atara Biotherapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Atara Biotherapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Atara Biotherapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Atara Biotherapeutics, Inc.

Sign Up Free
Corporate Identity

Atara Biotherapeutics, Inc. (Stock Symbol: ATRA) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Atara Biotherapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Atara Biotherapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Atara Biotherapeutics, Inc....

Unlock Full Company Profile

Get complete details about Atara Biotherapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis

Atara Biotherapeutics, Inc. generates annual revenues of $6 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Atara Biotherapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Atara Biotherapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Atara Biotherapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Atara Biotherapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Atara Biotherapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Atara Biotherapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Atara Biotherapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-31 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Asset Utilization Efficiency

Asset turnover ratio of 0.29x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 1.98 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.

Atara Biotherapeutics, Inc. (ATRA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Atara Biotherapeutics, Inc. stock analysis.

Deep dive into Atara Biotherapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Atara Biotherapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Atara Biotherapeutics, Inc.:

Market Cap $92M
Revenue/Share $0.66
FCF/Share $-3.28
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Atara Biotherapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Atara Biotherapeutics, Inc.: An ROE of 189.0% demonstrates excellent shareholder value creation.

ROE 189.0%
ROA -332.6%
ROIC -495.5%
Tax Rate 0.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Atara Biotherapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Atara Biotherapeutics, Inc.: A current ratio of 1.98 shows adequate liquidity.

Current Ratio 1.98x
D/E Ratio -1.57x
Financial Leverage -0.57x
Interest Coverage -24.7x
Working Capital $7M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Atara Biotherapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Atara Biotherapeutics, Inc.: Free cash flow of $-31M indicates cash challenges that need attention.

Operating Cash Flow -$47M
Free Cash Flow -$31M
Capital Spending $16M
FCF/Sales -500.0%
CapEx/Sales 253.7%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Atara Biotherapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Atara Biotherapeutics, Inc.: An asset turnover of 0.29x suggests room for improvement in asset utilization.

Asset Turnover 0.29x
Receivables Turnover 19.5x
Fixed Assets Turnover 151.1x
Days Sales Outstanding 19 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Atara Biotherapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Atara Biotherapeutics, Inc.: With annual revenue of $6M, Atara Biotherapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $6M
Operating Income -$70M
Net Income -$69M
R&D Expense $37M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 14%
Cash & Short-term Investments 3%
Total Liabilities 58%
Short-term Debt 6%
Accounts Receivable 0%
Dividend & Shareholder Information
Shares Outstanding 9M

Latest Atara Biotherapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Atara Biotherapeutics, Inc. (ATRA) stock price and investment outlook.

📰 Loading...

Where ATRA sits on the market map

Explore the map →

Atara Biotherapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Atara Biotherapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $230M x 4.0x
ABPO ██% $1M x x
ACOG ██% $207M x 3.9x
ADAPY ██% $8M x x
ADMA ██% $2.17B 12.8x 5.3x
ADPT ██% $3.86B x 27.0x
AGEN ██% $351M 3.8x x
AGTX ██% $800K x x
AIM ██% $7M x 0.9x
ALEC ██% $252M x x
ALGS ██% $39M x 1.2x
ALLO ██% $680M x 1.6x
ALVO ██% $1.90B x x
AMGN ██% $236.37B 27.0x 20.2x
APGE ██% $10.18B x x
APTN ██% $57M x x
APTOF ██% $4M x x
ARGX ██% $65.31B x x
ARMP ██% $217M x x
ARTV ██% $543M x 1.6x
ATRA ██% $92M x x
ATYR ██% $49M x 1.0x
AURA ██% $784M x 2.5x
AUTL ██% $596M x 8.0x
AVXL ██% $266M x 2.1x
BCAB ██% $2M x x
BCDA ██% $16M x 6.0x
BCLI ██% $12M x x
BCRX ██% $2.54B x x
BDTX ██% $122M x 1.3x
BEAM ██% $3.06B x 2.9x
BIIB ██% $32.98B 24.0x 1.8x
BKHA ██% $50M 97.5x x
BNTX ██% $26.06B x x
CABA ██% $588M x 2.8x
CADL ██% $973M x 7.7x
CCCC ██% $462M x 1.9x
CELZ ██% $7M x 0.8x
CERO ██% $790K x x
CGEM ██% $1.42B x 4.4x
CGEN ██% $245M 3.5x 2.4x
CGON ██% $6.59B x 6.4x
CGTX ██% $98M x 3.0x
CHRS ██% $219M x 3.6x
CLDI ██% $3M x 1.1x
CLLS ██% $334M x x
CMPX ██% $427M x 2.6x
COAG ██% $2.07B x 4.6x
CPMV ██% $440K x x
CRDF ██% $84M x 3.2x
CRDL ██% $252M x x
CRIS ██% $3M x 0.7x
CRSP ██% $5.46B x 3.1x
CSBR ██% $73M x 18.6x
CVM ██% $28M x 2.6x
DBVT ██% $861M x 5.4x
DNA ██% $434M x 1.0x
DNLI ██% $3.64B x 4.4x
DTIL ██% $194M x 4.3x
DYAI ██% $20M x x
EDIT ██% $470M x 4.5x
EIKN ██% $588M x 1.3x
ELUT ██% $36M 0.7x 2.3x
ENGN ██% $123M x 0.5x
ENTX ██% $519M x 71.5x
ENZN ██% $67M x 0.4x
ESLA ██% $31M x x
EVAX ██% $28M x x
EXEL ██% $14.69B 17.1x 8.0x
EXOZ ██% $64M x 17.4x
FATE ██% $289M x 1.9x
FDMT ██% $827M x 2.0x
FENC ██% $434M x 10.2x
GILD ██% $185.67B x 15.7x
GLUE ██% $1.18B x 2.4x
GNTA ██% $48M x 3.9x
GPLB ██% $180K x x
GRML ██% $15M x 0.3x
HALO ██% $12.57B 30.4x 87.5x
HUMA ██% $166M x 5.3x
IBRX ██% $8.51B x x
IKT ██% $330M x 2.2x
IMA ██% $55M x 0.4x
IMCR ██% $1.92B x 4.6x
IMTX ██% $1.46B x x
IMVT ██% $8.10B x 11.0x
INAB ██% $12M x 0.6x
INKT ██% $58M x x
INMB ██% $67M x 3.3x
INTS ██% $12M x 1.4x
IOVA ██% $3.98B x 5.4x
IPSC ██% $381M x 1.6x
IVVD ██% $237M x 1.3x
JATT ██% $95M x 0.5x
JSPR ██% $24M x 16.7x
KLRS ██% $93M x 1.6x
KOD ██% $2.22B x 36.4x
KRYS ██% $10.60B 43.9x 7.8x
KYMR ██% $9.82B x 6.5x
KYTX ██% $508M x 3.1x
LCTX ██% $273M x 4.5x
LENZ ██% $187M x 0.9x
LIFE ██% $3.91B x 80.1x
LIMN ██% $5M x 16.6x
LONA ██% $71M x 2.1x
LXEO ██% $384M x 1.6x
MAZE ██% $1.48B x 3.3x
MESO ██% $2.25B x x
MGTX ██% $1.31B 16.6x 6.1x
MGX ██% $44M x 0.4x
MOLN ██% $176M x x
MRNA ██% $58.07B x 8.6x
NBIX ██% $15.81B 22.4x 4.3x
NMRA ██% $256M x 5.7x
NVAX ██% $1.68B x x
OCGN ██% $448M x x
OTLK ██% $162M x x
PALI ██% $363M x 3.0x
PASG ██% $15M x 3.4x
PCVX ██% $8.86B x 3.2x
PHGE ██% $4M x 0.4x
PLUR ██% $18M x x
PLX ██% $214M 11.3x 3.0x
PMCB ██% $5M x 0.2x
PRME ██% $649M x 16.3x
PROK ██% $802M x x
PTHS ██% $91M x x
QGEN ██% $9.39B x 2.5x
QNCX ██% $32M x x
REPL ██% $1.42B x 13.4x
RGEN ██% $9.46B 227.7x 4.5x
RGNX ██% $590M x 8.2x
RLAY ██% $4.05B x 4.5x
RVMD ██% $45.00B x 17.3x
RXRX ██% $1.94B x 2.1x
SABS ██% $313M x 1.5x
SANA ██% $1.15B x 7.5x
SCLX ██% $38M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $62M x x
SLDB ██% $1.08B x 2.9x
SLXN ██% $2M x 46.8x
SNTI ██% $10M x x
SRRK ██% $6.73B x 26.5x
SRZN ██% $268M x x
STRO ██% $333M x x
TARA ██% $225M x 1.4x
TARS ██% $3.59B x 10.3x
TCRX ██% $48M x 0.7x
TECH ██% $11.31B 62.2x 5.4x
TECX ██% $572M x 2.6x
TIL ██% $52M x 0.5x
TNYA ██% $155M x 2.2x
TSHA ██% $1.79B x 4.6x
TVGN ██% $47M x x
TWST ██% $7.85B x 17.6x
VACH ██% $541M 80.4x x
VALN ██% $621M x x
VCEL ██% $2.07B 85.4x 5.6x
VIR ██% $1.92B x 2.0x
VISK ██% $69M x 0.4x
VIVS ██% $4M x x
VOR ██% $1.28B 2.0x x
VXRT ██% $121M 3.2x 1.5x
VYGR ██% $211M x 1.4x
WINT ██% $10K x x
XFOR ██% $388M x 2.5x
ZEOX ██% $9M x 13.1x
ZIVO ██% $14M x x
ZURA ██% $582M x 3.0x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Atara Biotherapeutics, Inc. Stock Forecast

How accurate are Atara Biotherapeutics, Inc. stock predictions?

Our AI model shows a 2% Spearman correlation coefficient for ATRA predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Atara Biotherapeutics, Inc. stock price forecasts?

Our analysis considers Atara Biotherapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Atara Biotherapeutics, Inc. a good investment in 2026?

Based on our AI analysis, Atara Biotherapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Atara Biotherapeutics, Inc. forecasts updated?

Atara Biotherapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Atara Biotherapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...